Experienced in WT1-Related Wilms Tumor Syndromes

Dr. Jan E. Duus

Hematology Oncology | Hematology | Oncology
75 Beekman St, 
Plattsburgh, NY 
Experienced in WT1-Related Wilms Tumor Syndromes
75 Beekman St, 
Plattsburgh, NY 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Jan Duus is a Hematologist Oncology specialist and a Hematologist in Plattsburgh, New York. Dr. Duus is rated as an Experienced provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Lung Cancer, Pleuropulmonary Blastoma, Small Cell Lung Cancer (SCLC), Non-Hodgkin Lymphoma, and Bone Marrow Aspiration.

His clinical research consists of participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Hematology
Oncology
Licenses
Internal Medicine in NY
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO

Locations

75 Beekman St, Plattsburgh, NY 12901

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

Randomized Phase II Open Label Study of Lenalidomide R-CHOP (R2CHOP) vs. RCHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone) in Patients With Newly Diagnosed Diffuse Large B Cell Lymphoma
Randomized Phase II Open Label Study of Lenalidomide R-CHOP (R2CHOP) vs. RCHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone) in Patients With Newly Diagnosed Diffuse Large B Cell Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Drug, Biological, Other
Study Drugs: Cyclophosphamide, Doxorubicin Hydrochloride, Lenalidomide, Prednisone, Rituximab, Vincristine Sulfate
Study Phase: Phase 2
Randomized Phase III Trial of Lenalidomide Versus Observation Alone in Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma
Randomized Phase III Trial of Lenalidomide Versus Observation Alone in Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Other, Drug
Study Drug: Lenalidomide
Study Phase: Phase 3
Randomized Phase III Trial of Bortezomib, Lenalidomide, and Dexamethasone (VRd) Versus Carfilzomib, Lenalidomide, and Dexamethasone (CRd) Followed by Limited or Indefinite Duration Lenalidomide Maintenance in Patients With Newly Diagnosed Symptomatic Multiple Myeloma (ENDURANCE)
Randomized Phase III Trial of Bortezomib, Lenalidomide, and Dexamethasone (VRd) Versus Carfilzomib, Lenalidomide, and Dexamethasone (CRd) Followed by Limited or Indefinite Duration Lenalidomide Maintenance in Patients With Newly Diagnosed Symptomatic Multiple Myeloma (ENDURANCE)
Enrollment Status: Active_not_recruiting
Publish Date: September 08, 2025
Intervention Type: Other, Drug
Study Drugs: Bortezomib, Carfilzomib, Dexamethasone, Lenalidomide
Study Phase: Phase 3
Chronic Venous Thrombosis: Relief With Adjunctive Catheter-Directed Therapy - The C-TRACT Trial
Chronic Venous Thrombosis: Relief With Adjunctive Catheter-Directed Therapy - The C-TRACT Trial
Enrollment Status: Active_not_recruiting
Publish Date: July 10, 2025
Intervention Type: Device
Study Phase: Not Applicable
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: January 13, 2025
Intervention Type: Other
Study Phase: Phase 3
A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel With or Without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel With or Without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: June 03, 2024
Intervention Type: Drug, Other
Study Drugs: Carboplatin, Cyclophosphamide, Doxorubicin Hydrochloride, Paclitaxel
Study Phase: Phase 3
View 5 Less Clinical Trials
Similar Doctors
Advanced in WT1-Related Wilms Tumor Syndromes
Dr. David J. Ospina
Hematology Oncology | Oncology | Hematology
Advanced in WT1-Related Wilms Tumor Syndromes
Dr. David J. Ospina
Hematology Oncology | Oncology | Hematology

Central Vermont Medical Center Inc

130 Fisher Rd, Suite 1 2, 
Berlin, VT 
 (55.8 miles away)
802-225-5400
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

David Ospina is a Hematologist Oncology specialist and an Oncologist in Berlin, Vermont. Dr. Ospina is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Primary Lymphoma of the Brain, Paget Disease of the Breast, Richter Syndrome, Chronic Lymphocytic Leukemia (CLL), and Bone Marrow Aspiration. Dr. Ospina is currently accepting new patients.

Advanced in WT1-Related Wilms Tumor Syndromes
Dr. Eric A. Pillemer
Hematology Oncology | Oncology
Advanced in WT1-Related Wilms Tumor Syndromes
Dr. Eric A. Pillemer
Hematology Oncology | Oncology

University Of Vermont Medical Center Inc

111 Colchester Ave, 
Burlington, VT 
 (20.4 miles away)
802-847-0000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Eric Pillemer is a Hematologist Oncology specialist and an Oncologist in Burlington, Vermont. Dr. Pillemer is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Upper Tract Urothelial Carcinoma (UTUC), Hairy Cell Leukemia (HCL), Neuroendocrine Tumor, and Paget Disease of the Breast.

Advanced in WT1-Related Wilms Tumor Syndromes
Dr. Steven Ades
Hematology Oncology | Hematology | Oncology
Advanced in WT1-Related Wilms Tumor Syndromes
Dr. Steven Ades
Hematology Oncology | Hematology | Oncology

University Of Vermont Medical Center Inc

1 S Prospect St, 
Burlington, VT 
 (20.2 miles away)
802-847-0000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Steven Ades is a Hematologist Oncology specialist and a Hematologist in Burlington, Vermont. Dr. Ades is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Colorectal Cancer, Familial Prostate Cancer, Penile Cancer, Upper Tract Urothelial Carcinoma (UTUC), and Bone Marrow Aspiration. Dr. Ades is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Duus's expertise for a condition
ConditionClose
    View All 12 Distinguished Conditions
    View All 33 Advanced Conditions
    View All 107 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile